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The aim was to evaluate human papillomavirus (HPV) ‘reflex genotyping’ in cases of minor cytological abnormalities detected in the
gynaecological screening programme in Stockholm, Sweden. Liquid-based cytology samples showing minor cytological abnormalities
were analysed using HPV genotyping (Linear Array, Roche diagnostics). Colposcopically directed cervical biopsies were obtained
and the HPV test results were correlated with the histological results. In all, 63% (70/112) of the samples were high-risk (HR) HPV
(HR-HPV) positive. A statistically significant correlation was found between high-grade cervical lesions and HR-HPV (P¼0.019),
among which HPV 16, 18, and 31 were the most important. The negative predictive value of HR-HPV detection for histologically
confirmed high-grade lesions was 100%. An age limit for HPV reflex testing may be motivated in cases of low-grade squamous
intraepithelial neoplasia (LSIL), because of high HR-HPV prevalence among younger women. By using HPV reflex genotyping,
additional extensive workup can safely be avoided in about 50% of all cases of atypical squamous cells of undetermined significance
(ASCUS) and LSIL among women X30 years. This screening strategy could potentially reduce the total abnormal cytology-reporting
rate in the Swedish screening programme by about 1% and provide more accurately directed follow-up, guided by cytological
appearance and HPV test results.
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Globally, cervical cancer is the second most common cancer, after
breast cancer, among women (Kamangar et al, 2006). Human
papillomavirus (HPV) infection is a prerequisite for development
of cervical cancer (Bosch et al, 1995; Walboomers et al, 1999). A
number of HPV types have been defined as high-risk (HR) HPV
(HR-HPV) types, based on their association with cervical cancer
(Mun ˜oz et al, 2006). However, HPV infection is also common
among healthy women. Generally, HPV infection is the most
common sexually transmitted infection, and particularly common
among young women (Bosch and de Sanjose ´, 2007). It is usually
asymptomatic and spontaneously cleared by the immune system
(Franco et al, 1999).
In Sweden, significant decreases in the incidence and mortality
of cervical cancer have been observed since the introduction of a
population-based gynaecological screening programme in the
1960s (Bergstro ¨m et al, 1999; Gunnell et al, 2007). However,
about 450 new cases of invasive cervical cancer are identified each
year. The failure to prevent these cases is due to incomplete
screening coverage, inadequate follow-up of abnormal smears, and
methodological limitations in sensitivity for the detection of
premalignant and malignant cervical lesions (Andersson-Ellstro ¨m
et al, 2000; Andersson et al, 2003; Andrae et al, 2008).
Liquid-based cytology (LBC) has shown higher sensitivity for
high-grade cervical lesions than conventional cytology (Strander
et al, 2007; Zhu et al, 2007). The proportion of abnormal findings
increases when conventional Pap smears are replaced by LBC
for screening. However, the positive predictive value (PPV)
for advanced lesions increases in laboratories with extensive
experience (Strander et al, 2007).
Today, in Sweden, about 3–5% of all smears show some kind of
abnormality, almost 80% of which are minor cytological changes. The
recommendations for the management of minor cytological abnorm-
alities vary in different parts of Sweden. In Stockholm County, all
abnormal cytology results lead to costly follow-up investigations with
repeat Pap smear and colposcopically directed biopsies.
In cases of minor cytological abnormalities, HPV testing can
more efficiently identify the small proportion of clinically
important lesions. Such an approach is internationally accepted
for cases of atypical squamous cells of undetermined significance
(ASCUS), but has not been generally recommended in cases
of low-grade squamous intraepithelial lesions (LSIL) because
of a high prevalence of oncogenic HPV in this group (Scherman
et al, 2002; Schiffman and Solomon, 2003; Arbyn et al, 2006;
Wright et al, 2007).
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sSuch triage can be performed in conjunction with LBC as a
reflex test and may further improve cytological evaluation. The
aim of this study was to determine the value of HPV genotyping as
a ‘reflex test’ in cases of minor cytological abnormalities detected
in the Swedish population-based primary screening programme.
MATERIALS AND METHODS
Study population and setting
Seven maternity health centres in the southern part of Stockholm
participated in this study. During the study period (September
2005–September 2006), 4204 liquid-based consecutively obtained
samples from routine screening were prepared, using the ThinPrep
2000 Processor (Cytyc Corporation, Boxborough, MA, USA)
(Linder, 1998).
Minor cytological abnormalities were found in 149 (3.5%) of
these samples, comprising the cytological classifications of ASCUS,
atypical glandular cells of undetermined significance (AGUS), and
LSIL.
The cytological diagnoses were defined using the Bethesda
nomenclature (Solomon et al, 2002). According to Swedish
recommendations, cases of koilocytosis without signs of dysplasia
are reported as non-pathologic. Therefore, the LSIL group contains
samples corresponding to cytological cervical intraepithelial
neoplasia grade 1 (CIN1) only. There were 93 cases of LSIL, 53
of ASCUS, and 3 of AGUS. The two latter groups will hereafter be
considered together and referred to as ASCUS.
Mean age of patients was 33 years, median age 30 years, and age
range 22–59 years. Women with ASCUS were older than women
with LSIL; mean ages of 35 years and 31 years, respectively
(P¼0.028), although the samples were consecutively derived from
the same screening cohort. The age range was similar for both
groups: 22–58 years for ASCUS and 22–59 years for LSIL.
Women with minor cytological abnormalities were referred for
further investigation, including gynaecological examination, col-
poscopy, directed biopsies, and repeat Pap smear. The histological
samples were evaluated and classified according to the CIN
classification (Richard, 1968). On the basis of the most severe
grade of CIN found, the histology findings were classified as within
normal limits (WNL), CIN1, or CIN grade 2 or a more advanced
lesion (CIN2þ). The histological follow-up results were traced
through the medical and laboratory records and through the
Stockholm Oncology Center. Only histological material obtained
within 1 year of cytological screening were registered. Ethical
approval was obtained in December 2004 (No. 04-679/3).
HPV analysis
Briefly, 2ml of the remaining cell suspension from the liquid based
cytology samples were taken for DNA extraction by a MagNA
Pure LC Robot (Roche
s). HPV-DNA detection and genotyping
were performed using the Linear Array HPV Genotyping Test
(LA) according to the manual provided by the manufacturer
(Roche Diagnostics). Thus, HPV-DNA was amplified by PCR using
a pool of biotin-labelled primers that hybridise in the L1 region.
Then, HPV-DNA amplicons were chemically denatured to single-
stranded DNA, hybridised with matching type-specific DNA
probes, immobilized on nylon strips, and detected by colorimetric
determination.
The 37 HPV types included in the LA test were divided into
three ‘risk categories’: the HR-HPV types 16, 18, 31, 33, 35, 39, 45,
51, 52, 56, 58, and 59, the probably HR (pHR)-HPV types 26, 53,
66, 68, 73, and 82; and those considered to be low-risk (LR)-HPV
or of undetermined risk including types 6, 11, 40, 42, 54, 55, 61, 62,
64, 67, 69, 70, 71, 72, 81, 83, 84, IS39, and CP6108. Those of
undetermined risk (shown in italics) will be considered together
with the LR-HPV types (Mun ˜oz et al, 2006).
The ability of the HPV test to identify or exclude a high-grade
cervical lesion was evaluated with the histopathology as gold
standard.
Statistical analysis
To determine the statistical significance of differences between
groups, w
2 statistics (exact tests), and Student’s t-test were used.
The null hypothesis of no difference was rejected at a significance
level of Pp0.05.
The primary end point was histopathologically verified CIN2þ.
The sensitivity, specificity, negative predictive value (NPV), and
PPV of HR-HPV detection using LA to detect such high-grade
lesions (CIN2þ) were calculated, with 95% confidence intervals
(CI; Newcombe, 1998).
RESULTS
Histological findings
Of the 149 cases of mild cytological abnormalities studied,
histopathological follow-up was obtained in 112 cases. Histology
results were available for 39/56 (70%) of the ASCUS and 73/93
(78%) of the LSIL samples. These are the cases that will be
discussed here later.
The cytological findings in relation to the histological diagnosis
in 112 women are summarised in Table 1. Among women with
minor cytological abnormalities, 39/112 (35%) CIN1 and 15/112
(13%) CIN2þ cases were detected. In cases reported as ASCUS,
11/39 (28%) CIN1 and 5/39 (13%) CIN2þ lesions were found. In
cases of LSIL, there was a slightly higher detection rate of CIN1
(28/73 cases or 38%), but a similar rate of CIN2þ (10/73 cases or
14%).
HPV infection and histological findings
In all, 81% (91/112) of all samples were HPV positive. There was a
significant proportion of multiple infections and overlap of
infections with HPV types from one, two, or all three risk
categories (HR-, pHR-, and LR-HPV).
The prevalence of HPV-infected samples increased with the
grade of dysplasia: 74% (43/58) of the WNL, 85% (33/39) of the
CIN1, and 100% (15/15) of the CIN2þ cases were HPV positive
(P¼0.026).
Figure 1 demonstrates the prevalence of the different HPV risk
categories, including cases of single and multiple HPV infections,
with or without coinfections by HPV types belonging to other risk
categories. All 15 cases of CIN2þ were HR-HPV positive (Figure 1)
compared to 56% (22/39) of the CIN1 and 57% (33/58) of the WNL
Table 1 Liquid-based cytology findings correlated to histological
diagnosis in 112 women with minor cytological abnormalities
Histological diagnosis
Cytology WNL (%) CIN1 (%) CIN2+ (%) Total (%)
ASCUS 23 (59) 11 (28) 5 (13) 39 (100)
LSIL 35 (48) 28 (38) 10 (14) 73 (100)
Total 58 (52) 39 (35) 15 (13) 112 (100)
ASCUS¼atypical squamous cells of undetermined significance; CIN1¼cervical
intraepithelial neoplasia grade 1; CIN2þ¼cervical intraepithelial neoplasia grade 2
or a more advanced lesion; LSIL¼low-grade squamous intraepithelial lesion;
WNL¼within normal limits. The differences in the detection of histological CIN1
and CIN2+ were not statistically significant (P¼0.410).
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scases (P¼0.019). In all, 63% (70/112) of the samples were HR-HPV
positive (Table 2). In this cytologically selected material, the NPV
for the LA-HPV test to detect a CIN2þ lesion was 100% (95% CI:
90–100%). The statistically significant relation between the HR-
HPV group and CIN2þ disappears if the pHR-HPV types are
considered as HR-HPV (P¼0.112).
In Figure 2, the HPV infection pattern is described as
‘hierarchic’ risk categories; the HPV test results have been
classified into risk categories according to the HPV type/types of
the highest HPV risk category found in each sample. Pure LR-HPV
infection was markedly overrepresented in CIN1, present in 23% of
cases (9/39), compared with 7% (4/58) in the WNL cases, and the
prevalence of pHR-HPV positive but HR-HPV negative cases
decreased with increasing grade of CIN (P¼0.018).
Distribution of HPV types and histological findings
To detect all cases of CIN2þ, the assay had to accurately detect at
least the HPV types 16, 18, 31, 52, and 58. HPV 45 was detected as
frequently as HPV 52 and 58 among the CIN2þ cases (2/15 cases
or 13%); however, never as a single HR-HPV infection. In this
limited material, we were able to demonstrate a significant
correlation between HPV types 16 (P¼0.045), 18 (P¼0.039),
and 31 (P¼0.006) with high-grade cervical lesions. Presence of
Table 2 Performance of HR-HPV detection using linear array to detect histologically confirmed CIN2+ in cases of ASCUS and LSIL, with respect to
sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV) with 95% confidence intervals (CI)
Cytology
classification
Probability of HR-HPV
presence (%) (95% CI)
Sensitivity (%)
(95% CI)
Specificity (%)
(95% CI)
PPV (%)
(95% CI)
NPV (%)
(95% CI)
ASCUS+LSIL
(n¼112)
63 (53–71) 100 (75–100) 43 (33–54) 21 (13–33) 100 (90–100)
ASCUS (n¼39) 46 (30–63) 100 (46–100) 62 (44–77) 28 (11–54) 100 (81–100)
LSIL (n¼73) 71 (59–81) 100 (66–100) 33 (22–46) 19 (10–33) 100 (81–100)
LSIL X30yrs
(n¼32)
53 (35–70) 100 (40–100) 54 (34–72) 24 (8–50) 100 (75–100)
ASCUS+LSIL
X30years (n¼71)
49 (37–61) 100 (63–100) 58 (45–70) 26 (13–44) 100 (88–100)
ASCUS¼atypical squamous cells of undetermined significance; CIN2þ¼cervical intraepithelial neoplasia grade 2 or a more advanced lesion; HPV¼human papilloma virus;
HR HPV¼high risk HPV; LSIL¼low grade squamous intraepithelial lesion; WNL¼within normal limits.
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Figure 2 Prevalence of HPV hierarchic risk categories related to
histological diagnosis in 112 cases of minor cytological abnormalities. The
HPV test results have been classified into risk categories according to the
HPV type/types of the highest HPV risk category found in each sample.
Using this description of the HPV infection pattern, there is no overlap
between the different HPV risk categories. HR-HPV pos (black
bars)¼samples positive for at least one HR-HPV type, with or without
pHR- and/or LR-HPV coinfection. pHR-HPV pos, HR-HPV neg (dark grey
bars)¼samples positive for at least one pHR-HPV type but negative for
HR-HPV, with or without LR-HPV coinfection. LR-HPV pos only (light grey
bars)¼ samples positive for at least one LR-HPV type, without HR- and
pHR-HPV coinfection. HPV neg (white bars)¼samples negative for all
detectable HPV types.
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Figure 1 Prevalence of HPV risk categories related to histological
diagnosis in 112 cases of minor cytological abnormalities. Single and
multiple HPV infections are present within all risk categories. Since infection
by HPV types of different risk categories overlap each other, the sum of the
HR-, pHR-, and LR-HPV prevalences in each histological diagnosis group
can exceed 100%. WNL (n¼58)¼within normal limits. CIN1
(n¼39)¼cervical intraepithelial neoplasia grade 1. CIN2þ (n¼15):
cervical intraepithelial neoplasia grade 2 or a more advanced lesion. HR-
HPV pos (black bars)¼samples positive for at least one HR-HPV type,
with or without pHR- and/or LR-HPV coinfection. pHR-HPV pos (dark
grey bars)¼samples positive for at least one pHR-HPV type, with or
without HR- and/or LR-HPV coinfection. LR-HPV pos (light grey
bars)¼samples positive for at least one LR-HPV type, with or without
HR- and/or pHR-HPV coinfection.
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scoinfection with other HPV types has not been taken
into consideration when performing the calculations (Figure 3,
Supplementary Table 1). Among patients with minor cytological
lesions and subsequent histological findings of CIN2þ, the HPV
types 16, 31, and 18 clearly stand out as the most common, present
in single or multiple HPV infections in 40% (6/15), 33% (5/15), and
27% (4/15) of the cases, respectively. Together, they were present
in 73% (11/15) of the samples. Out of the 15 CIN2þ cases, 53%
(8/15) were infected with HPV 16 and/or HPV 18; however, only
three of these cases were not infected with additional HR-HPV
types.
In the CIN1 and WNL cases, the HPV types were more evenly
distributed. Among the cases of CIN1, there was a relatively high
proportion of the LR-HPV types HPV 42, 84, and CP6108. HPV 6
was present in only 4% (5/112) of all cases, and there were no HPV
11 infections.
Multiple HPV infection and degree of CIN
In all, 54% (61/112) of the cases had multiple HPV infection, and of
all 91 HPV-infected individuals, 67% (61/91) were infected by
more than one HPV type. Multiple HPV infection was slightly
more common in cases of histological CIN2þ than in CIN1 and
WNL cases (73, 64, and 67%, respectively). Among the HR-HPV-
positive samples, 41% (29/70) were infected by more than one HR-
HPV type. Also in the case of HR-HPV, multiple infections were
slightly more common in cases of CIN2þ (Figure 4) than in CIN1
and WNL cases (47 vs 36, and 42%, respectively). However, none of
these differences were statistically significant, but of course,
a multiple HPV infection increases the probability of harbouring
a highly oncogenic HPV type.
DISCUSSION
In the Swedish population-based gynaecological screening pro-
gramme, abnormal samples are associated with follow-up inves-
tigations, and clinical recommendations for the management of
minor cytological abnormalities vary. In Stockholm County, all
women with any degree of atypia are referred for a colposcopic
examination and targeting biopsy. The question of whether HPV
testing may improve the Swedish screening programme is under
discussion, especially for use as a follow-up test to identify possible
precancerous lesions among mild cytological abnormalities and
distinguish these from reactive and degenerative lesions. This is an
approach, which is widely accepted internationally (see introduc-
tion), but has only been randomly adopted in Sweden.
Reporting rates in the Scandinavian screening programmes
differ from those in the Anglo-Saxon world. Scandinavian
cytologists tend to rate the samples as WNL more frequently than
British or American cytologists (abnormal smear rate: 3–5 vs 10–
15%), discounting subtle changes in deference to achieving
cytological certainty (Scott et al, 2002). In spite of these
differences, our results suggest that the value of HR-HPV detection
in cases of minor cytological abnormalities is high also in a
Swedish context.
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Figure 3 Relative distribution of HR-, pHR-, and LR-HPV types in liquid-based cytology samples showing minor cytological abnormalities, related to
histological diagnosis: WNL (n¼58; light grey bars), CIN1 (n¼39; dark grey bars), and CIN2þ (n¼15; black bars). The corresponding figures are
presented in detail in Supplementary Table 1.
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Figure 4 Prevalence of single vs multiple HR-HPV infections in HR-HPV-
positive cases related to histological diagnosis: WNL (n¼33), CIN1
(n¼22), and CIN2þ (n¼15). Single HR-HPV infections (light grey bars).
Multiple HR-HPV infections (black bars).
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sAmong cases of minor cytological abnormalities detected using
LBC, HR-HPV detection using LA has a 100% (95% CI: 90–100%)
NPV for high-grade cervical dysplasia during a maximum follow-
up time of 1 year (Table 2). This is similar to the findings in a large
scale prospective study including cases of ASCUS where carcino-
genic HPV detection using the same HPV test showed an excellent
NPV (95.67%; 95% CI: 94.22–96.85%) for 2-year cumulative
CIN2þ (Castle et al, 2008). In this study, we used a different
definition for carcinogenic or HR-HPV, classifying HPV 66 and 68
as pHR-HPV types. This probably affects the performance of the
HPV test only marginally. Our results suggest that the pHR-HPV
group is of little of no importance in a screening context; however,
this might need further consideration.
In the LSIL group, HR-HPV prevalence is high, about 80–85%,
among women younger than 30 years, and drops to about 50%
among women aged 30 years, or older. For this reason, specificity
of HPV detection test can be improved by setting an age limit of 30
years for HPV reflex testing in cases of LSIL (Table 2). An age limit
at 35 years in cases of LSIL has been suggested (Ronco et al, 2007),
yielding a somewhat higher specificity for histologically confirmed
CIN2þ (using Hybrid Capture II for HPV detection), compared to
our findings for women aged 30–59 years.
In cases of ASCUS, where HR-HPV prevalence is considerably
lower (about 40%), and the HR-HPV prevalence was not
significantly higher among women under the age of 30 years than
among older women, for which reason the diagnostic value of HPV
testing in this group is independent of age.
Thus, in HPV triage using the LA-HPV test for all cases of
ASCUS and for cases of LSIL with age X30 years, the need for
extensive follow-up investigations would be reduced by about 50%,
with good safety. In such cases, cytological evaluation and
virological analysis could be performed using the same material
(reflex testing). Because there is only one sampling event, sampling
error would be reduced. Screening programme costs would also be
reduced, because both analyses can be performed without recalling
the patient. The decision of whether to set an age limit for HPV
reflex testing in LSIL cases should be based on health–economic
calculations.
According to our results, only the HR-HPV group had a statistically
significant correlation with CIN2þ, for which the HR-HPV types 31,
18, and 16 were the most important (Figure 3, Supplementary Table 1).
In this small material, in order to identify all cases of high-grade
cervical lesions, the HPV test had to accurately detect HPV 16, 18, 31,
52, and 58. These HPV types are represented among the main
worldwide oncogenic HPV types (HPV 16, 18, 31, 33, 35, 45, 52, and
58), which account for about 88% of all cervical cancer cases worldwide
(Smiths et al, 2007). However, since a high NPV is necessary in a reflex
screening situation, all HR-HPV types need to be accurately detected.
In cases where histology findings were WNL or CIN1, more than
50% were HR-HPV positive. These women need to be followed up,
given their elevated risk for developing a high-grade cervical
lesion. Repeated HPV genotyping allows diagnosing persistent
HPV infection and risk stratification of women with cytological
abnormalities, and might be useful for clinical management
(Wheeler et al, 2006; Bulkmans et al, 2007; Naucler et al, 2007).
However, the exact design of such follow-up needs to be studied
further.
Liquid-based cytology (LBC) combined with reflex detection of
HR-HPV types in cases of minor cytological abnormalities
probably provides increased sensitivity and increased specificity
for the detection of high-grade cervical lesions, when used in
population-based screening.
Based on the fact that minor cytological abnormalities constitute
75–80% of all abnormal cytological results in Sweden, our
preliminary calculations show that combining LBC with HPV
reflex testing in gynaecological screening reduces the total
abnormal cytology-reporting rate by approximately 1%. However,
LBC screening generally yields a somewhat higher abnormal
cytology-reporting rate than conventional cytology screening.
Conventional cytology is the predominating screening method in
Sweden today, which makes the potential 1% reduction of the
abnormal cytology-reporting rate uncertain. The main value of
introducing LBC combined with HPV reflex testing is probably an
improved ability to identify women with an increased risk of
developing premalignant and malignant cervical lesions, without
increasing the abnormal cytology-reporting rate. A cost–efficiency
analysis is ongoing. Unnecessary investigations and unnecessary
psychological stress could be avoided, and resources could be used
for more accurately directed follow-up of women with abnormal
cytological findings.
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